Findings showed Capvaxive was noninferior to PPSV23 for each of the 12 serotypes present between the 2 vaccines. Topline data were announced from a phase 3 trial evaluating Merck’s 21-valent ...

Vaxcyte (NASDAQ:PCVX) executives used a presentation at an annual biotech summit to highlight progress across the company’s ...

In adults living with HIV, the 21-valent pneumococcal conjugate vaccine (PCV) V116 was well tolerated and effective against all 21 target serotypes. The immune responses were comparable to those ...

Pneumococcal conjugate vaccines (PCVs) reduce disease and colonization by the serotypes they cover. As of now, the Advisory Committee on Immunization Practices (ACIP) recommends that PCV15 and PCV20 ...

Vaxcyte (NASDAQ:PCVX) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight progress in late-stage development of its pneumococcal conjugate vaccine (PCV) ...

—Among adults, coverage and preventable burdens were lowest for pneumococcal conjugate vaccine (PCV) 15 and highest for PCV31, with PCV21 preventing notable burdens of both acute respiratory ...

Vaxcyte Inc. (NASDAQ:PCVX) is one of the best stocks to buy and hold for the next 6 months. On February 11, Vaxcyte Inc. (NASDAQ:PCVX) confirmed the dosing of the first participants in its OPUS-3 ...

Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...